Protiveris Strengthens Executive Team With Key CTO Appointment

Apr 19, 2005, 01:00 ET from Protiveris Inc.

    ROCKVILLE, Md., April 19 /PRNewswire/ -- Protiveris Inc., a
 bio-nanotechnology company commercializing microcantilever technologies to
 facilitate biomolecular research, today announced the appointment of Gregory
 Kellogg Ph.D. as Chief Technology Officer.
     "I am very pleased to welcome Greg to the Protiveris management team.  He
 has been key in building the success of several groundbreaking biotechnology
 companies, including Network Biosystems and Tecan Boston," said Robert Menzi,
 Chief Operating Officer at Protiveris. "Greg's skill and depth of experience
 complement our existing management strengths and we look forward to his
 contribution to the further development and commercialization of our VeriScan
     Dr. Kellogg brings to Protiveris a strong history of innovation in
 developing technology and building R&D organizations. Formerly Vice President
 of Research at Network Biosystems, Dr Kellogg managed the development of a
 microfabrication-based electrophoresis system for forensic applications. Prior
 positions include Director of R&D at IQUUM, where he planned and executed
 product development feasibility programs, and Chief Scientist at Tecan Boston
 (formerly Gamera Bioscience Corporation), where he developed the technical
 foundation of the company's microfluidic platform. This technology was
 introduced into the drug discovery marketplace as the LabCD(TM), an
 automation-compatible system for ADMET. Dr. Kellogg received his Ph.D. in
 physics from Harvard University and conducted his post-doctoral research at
 Massachusetts Institute of Technology in the Department of Materials Science
 and Engineering. He has published extensively and is an inventor on more than
 10 issued US and European patents.
     About Protiveris, Inc.
     Protiveris is committed to establishing the standard of performance for
 proteomic research tools. The VeriScan(TM) 3000 bench-top biochip system
 measures and analyzes biomolecular and chemical interactions to enable more
 efficient and accurate research outcomes. The biochip utilizes arrays of
 microcantilevers with customizable surfaces to detect interactions between
 proteins, antibodies, antigens, or DNA. This label-free system provides
 researchers with the ability to create high content assays that deliver real
 time data. More information about Protiveris, their technology, products, and
 services can be found at the company's web site at .

SOURCE Protiveris Inc.